Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 13/20 | 0.58 |
| ▸ | BUB1 | O43683 | 4/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14488292 | 0.89 | PDE5A (0.45) | PDE5A | |
| SCHEMBL16370319 | 0.87 | PDE5A (0.45) | PDE5ABUB1AKR1C3 | |
| SCHEMBL14488226 | 0.86 | PDE5A (0.42) | PDE5A | |
| SCHEMBL326700 | 0.85 | PDE5A (0.55) | PDE5A | |
| SCHEMBL9913987 | 0.85 | PDE5A (0.42) | PDE5A | |
| SCHEMBL9913940 | 0.85 | PDE5A (0.49) | PDE5A | |
| SCHEMBL15937547 | 0.85 | PDE5A (0.41) | PDE5ABUB1 | |
| SCHEMBL15944482 | 0.84 | PDE5A (0.43) | PDE5A | |
| SCHEMBL9914040 | 0.84 | PDE5A (0.51) | PDE5A | |
| SCHEMBL15937792 | 0.84 | PDE5A (0.45) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2729476-B1 | HETEROARYL SUBSTITUTED PYRAZOLOPYRIDINES AND THEIR USE AS STIMULATORS OF SOLUBLE GUANYLATE CYCLASE | BAYER IP GMBH (DE) | 2017-08-23 | — | — | EP | disclosed |
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| US-9505786-B2 | Substituted annulated triazines and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-29 | — | — | US | disclosed |
| EP-2699578-B1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER IP GMBH (DE) | 2016-04-20 | — | — | EP | disclosed |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-01 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-9090610-B2 | Fluoroalkyl-substituted pyrazolopyridines and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-12-04 | — | — | US | disclosed |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140100229-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-04-10 | — | — | US | disclosed |
| EP-2699578-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | Bayer Intellectual Property GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2012143510-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274754-A1 | SUBSTITUTED ANNULATED TRIAZINES AND USE THEREOF | TPMT, GOT2, TYMP | PDE5A 1225/4885BUB1 1036/4885AKR1C3 2571/4885 |
| US-20140228366-A1 | HETEROARYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | GUCY1A2, GUCY1B2, GUCY1B1 | PDE5A 8/4885BUB1 4674/4885AKR1C3 1950/4885 |
| US-20140100229-A1 | FLUOROALKYL-SUBSTITUTED PYRAZOLOPYRIDINES AND USE THEREOF | PON1, QDPR, FABP3 | PDE5A 304/4885BUB1 2184/4885AKR1C3 1840/4885 |
| US-20140357637-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | TYMP, DPYD, TYMS | PDE5A 1705/4885BUB1 595/4885AKR1C3 2602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.